AKN-028 (TFA)

• UNSPSC Description:

  AKN-028 TFA, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC50 value of 6?nM. AKN-028 TFA inhibits FLT3 autophosphorylation. AKN-028 TFA induces dose-dependent cytotoxic response (mean IC50=1?μM). AKN-028 TFA induces apoptosisby activation of caspase 3. AKN-028 TFA can be used in research of acute myeloid leukemia (AML)[1].

• Target Antigen:

  Apoptosis; Caspase; FLT3

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Protein Tyrosine Kinase/RTK

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/akn-028-tfa.html

• Smiles:

  NC1=NC=C(C2=CC=NC=C2)N=C1NC3=CC4=C(NC=C4)C=C3.O=C(O)C(F)(F)F

• Molecular Weight:

  416.36

• References & Citations:

  [1]A Eriksson, et al. The Novel Tyrosine Kinase Inhibitor AKN-028 Has Significant Antileukemic Activity in Cell Lines and Primary Cultures of Acute Myeloid Leukemia. Blood Cancer J. 2012 Aug 3;2(8):e81.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  1175017-91-0